RxDoctor Payments Data

Luis Vazquez Moyet, MD

Nephrology · Guayama, PRNPI 1831398429

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,158 of the $3,882 with a category attached, or 81.3%. 16 manufacturers reported payments, led by AstraZeneca at 26.2% of the total. Reporting peaked in 2019 at $1,211 and has fallen 72.0% since, to $340 in 2025.

$3,882in general payments, 2019–2025

Across 78 payments — averaging $49.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Fresenius USA Marketing, Inc.$901
  • Johnson & Johnson$251
  • Boehringer Ingelheim$230
  • Bayer$190
  • Calliditas Therapeutics US Inc.$185
  • plus $1K from 10 others

What the payments were for

  • Travel & lodging$71018%
  • Food & beverage$3,15881%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,882 in reported general payments places this provider in the 80th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,666
Medicare patients
36
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol303$196,852
JardianceEmpagliflozin200$132,239
KerendiaFinerenone114$78,692
TradjentaLinagliptin127$68,216
Sevelamer Carbonate266$33,046
GlyxambiEmpagliflozin/Linagliptin32$20,481
LokelmaSodium Zirconium Cyclosilicate25$16,397
Lanthanum Carbonate26$12,085
DapagliflozinDapagliflozin Propanediol11$4,368
Allopurinol491$2,943
Losartan Potassium344$2,581
Hydralazine Hcl191$2,374
Pioglitazone Hcl147$1,972
Calcitriol81$1,798
Calcium Acetate19$1,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$230$220,936359 claims
AstraZenecaFarxiga, Lokelma$1,018$213,249328 claims
BayerKerendia$190$78,692114 claims
ANI Pharmaceuticals, Inc.Valsartan$87$96239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Guayama

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →